TIAA CREF Investment Management LLC Buys New Holdings in Novelion Therapeutics Inc. (NVLN)

TIAA CREF Investment Management LLC bought a new position in shares of Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSE:QLT) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 40,795 shares of the biotechnology company’s stock, valued at approximately $377,000. TIAA CREF Investment Management LLC owned about 0.22% of Novelion Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in Novelion Therapeutics by 167.2% during the 1st quarter. JPMorgan Chase & Co. now owns 10,292 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 6,440 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in Novelion Therapeutics during the 2nd quarter worth approximately $102,000. Franklin Resources Inc. grew its holdings in Novelion Therapeutics by 4.2% during the 2nd quarter. Franklin Resources Inc. now owns 12,798 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 511 shares during the last quarter. Rhumbline Advisers bought a new stake in Novelion Therapeutics during the 2nd quarter worth approximately $146,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in Novelion Therapeutics during the 2nd quarter worth approximately $240,000. 78.23% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/11/22/tiaa-cref-investment-management-llc-buys-new-holdings-in-novelion-therapeutics-inc-nvln.html.

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada dropped their price target on shares of Novelion Therapeutics from $9.00 to $8.00 and set a “sector perform” rating on the stock in a research report on Friday, November 10th. ValuEngine downgraded shares of Novelion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 12th. Finally, Zacks Investment Research downgraded shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th.

Novelion Therapeutics Inc. (NASDAQ:NVLN) opened at $4.52 on Wednesday. Novelion Therapeutics Inc. has a 1 year low of $4.19 and a 1 year high of $13.80. The company has a debt-to-equity ratio of 6.53, a quick ratio of 1.28 and a current ratio of 1.45.

About Novelion Therapeutics

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Want to see what other hedge funds are holding NVLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSE:QLT).

Institutional Ownership by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Receive News & Ratings for Novelion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply